XOMALooks like a round top to me, looks like a bearish structure to me, up above the resistance level around 27
X0M trade ideas
XOMA CORP daily analysisHi friends
the daily analysis shows that it will experience with a high probability an uptrend but at the same time you have to be vigilant of the change towards the opposite direction
XOM: Wedges and a MegaphoneIf there were options for XOM, I would open and long straddle given the likelihood of big future volatility. There aren't, so I'm flipping the coin long on the thesis that the broader US market is in a bull.
<TradeVSA> XOMA - Continue to show strengthStrength in the chart:
1. Confirmation on accumulation
2. Back to previous support
3. Testing resistance
4. Potential to move sideway before breakout
Send us your preference stock to review based on TradeVSA chart by comment at below.
Disclaimer
This information only serves as reference information and does not constitute a buy or sell call. Conduct your own research and assessment before deciding to buy or sell any stock
$XOMA KEEP ON WATCH FOR BREAKOUTXoma corp has just received some glowing recommendations, one of which is from H.C Wainwright analyst Joseph Pantginis who has a buy rating with a $30 price target. He wrote,
"We reiterate our Buy rating and $30 target. We highlight that we currently omit the 38 undisclosed partnered assets at the company, and look to provide potential contribution once identification and terms are delineated. Further, we do not include valuation contribution from projected cash flow from expected milestone payments from partners. Our clinical NPV model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
The recent earnings report surprised many as the company turned a $3.8 million loss in 2018 to a $1.88 million profit in the first quarter, the stock has had a considerable jump in recent days but there is plenty of gains still to be had.
Analyst average rating Overweight
Analysts Price target $27.50
Short Interest 17%
Company Description
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab.
Long term XOMA LongXOMA broke down past support and second support. Look for the corss back up on the MACD to buy.
XOMA Clearly Bearish Since ThanksgivingInsider selling and warrant offering looks like a short term top.
XOMA- short term bullishXOMA short term bullish. Nice reversal pattern @ .62%Fibo, bullish divergence on oscillators. The huge gap is not likely to be filled soon and longer term the chart is showing bearish signs.
